GSK's Jemperli endometrial cancer drug improves survival time with chemotherapy, reducing disease progression by 37%.
GSK's Jemperli endometrial cancer drug shows improved survival time when combined with chemotherapy, reducing disease progression by 37% and improving progression-free survival when combined with GSK's Zejula. The UK drugmaker expects US regulators to accept the data for review, aiming to expand the use of the medicine. In late-stage RUBY trial, Jemperli increased overall survival by over 16 months, meeting its main goal.
March 16, 2024
6 Articles